Novavax: presents its 2025 growth strategy
(CercleFinance.com) - Novavax enters 2025 with an ambitious growth strategy aimed at maximizing the impact of its cutting-edge technology.
NB: pmt -5.8%.
The company is focusing on strategic partnerships for its R&D programs as well as for its Matrix-M adjuvant, with the aim of innovating vaccines for global health.
The group is also highlighting its unique technology platform, combining recombinant protein nanoparticles and Matrix-M adjuvant, to stimulate powerful and long-lasting immune responses.
Novavax continues to diversify its pipeline, with programs in high-value areas and unmet medical needs, such as respiratory viruses, influenza, respiratory syncytial virus (RSV), and infections like shingles and Clostridium difficile colitis.
At the same time, the company says it is exploring new opportunities in therapeutic areas such as oncology.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
NB: pmt -5.8%.
The company is focusing on strategic partnerships for its R&D programs as well as for its Matrix-M adjuvant, with the aim of innovating vaccines for global health.
The group is also highlighting its unique technology platform, combining recombinant protein nanoparticles and Matrix-M adjuvant, to stimulate powerful and long-lasting immune responses.
Novavax continues to diversify its pipeline, with programs in high-value areas and unmet medical needs, such as respiratory viruses, influenza, respiratory syncytial virus (RSV), and infections like shingles and Clostridium difficile colitis.
At the same time, the company says it is exploring new opportunities in therapeutic areas such as oncology.
Copyright (c) 2025 CercleFinance.com. All rights reserved.